Physician profile
Jay Mulaney
NPI 1730155615
$3,066.33
in general payments reported to CMS, 2019-2025
22 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $209 · 2021: $762 · 2022: $144 · 2023: $209 · 2024: $237 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $503.89 | 2019 | |
| Aerie Pharmaceuticals, INC. | $472.22 | 2019-2021 | |
| Alcon Vision LLC | $448.32 | 2019-2024 | Rocklatan |
| Allergan, INC. | $296.32 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $281.09 | 2023-2025 | Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $240.68 | 2020-2021 | |
| Halozyme INC | $146.27 | 2019-2025 | Hylenex Recombinant |
| Kala Pharmaceuticals, INC. | $144.43 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $121.01 | 2019-2021 | |
| Ivantis, INC | $100.96 | 2021 | |
| Sight Sciences, INC. | $100.39 | 2019 | |
| Ocular Therapeutix, INC. | $50.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $26.86 | 2025 | Syfovre |
| Amgen INC. | $25.51 | 2025 | Tepezza |
| Abbvie INC. | $22.03 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Oyster Point Pharma, INC. | $18.97 | 2023 | Tyrvaya |
| Rayner Intraocular Lenses Limited | $16.81 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.46 | 2021 | |
| Astellas Pharma US INC | $14.71 | 2024 | Izervay |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Mulaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.